Achillion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The Company is engaged in the development of antivirals for the treatment of chronic hepatitis C infection (HCV), and the development of antibacterials for the treatment of resistant bacterial infections. The Company focuses on the development of four drug candidates for the treatment of HCV: ACH-1625, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase IIa clinical trial, ACH-2684, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial; ACH-2928, a NS5A inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial, and ACH-3102, a NS5A inhibitor for the treatment of HCV, which is being prepared for investigational new drug (IND), filing and initiation of a phase I clinical trial.
Achillion Pharmaceuticals Inc
ACHN:NASDAQ
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
| 7.77 | 0.21 2.78% | 0.00% | 823,358 | 675.6K |
Market data is delayed by at least 20 minutes.
| Profitability | ACHN | |
| Gross Margin (TTM) | -- | |
| Operating Margin (TTM) | -1,814.08% | |
| Pretax Margin (TTM) | -1,807.71% | |
| Net Profit Margin (TTM) | -1,807.71% | |
| * Data above as of Dec 31, 2012 | ||
| Valuation | ACHN | |
| P/E excluding extraordinary items (TTM) | -- | |
| P/E Normalized (MRFY) | -- | |
| P/Sales (TTM) | 287.8x | |
| P/Tangible book (TTM) | 10.4x | |
| P/Cash Flow (TTM) | -- | |
| * Data above as of May 17, 2013 | ||
| Financial Strength | ACHN | |
| Current Ratio (MRQ) | 7.4 | |
| Quick Ratio (MRQ) | -- | |
| LT Debt/Equity (MRQ) | 0.0 | |
| Total Debt/Equity (MRQ) | 0.0 | |
| Payout Ratio (TTM) | -- | |
| * Data above as of Dec 31, 2012 | ||
| Management Effectiveness | ACHN | |
| Return on Assets (TTM) | -57.42% | |
| Return on Equity (TTM) | -65.90% | |
| Return on Investments (TTM) | -64.52% | |
| * Data above as of Dec 31, 2012 | ||
| Growth | ACHN | |
| Sales (5Yr) | -8.38% | |
| EPS (TTM over TTM) | 7.91% | |
| Dividend Growth (5Yr) | -- | |
| * Data above as of Dec 31, 2012 | ||
| Income Statement | ACHN | |
| EBITDA (MRQ) | -11.3M | |
| Earnings before taxes (MRQ) | -11.2M | |
| Net Income (MRQ) | -11.2M | |
| Normalized earnings before taxes (MRQ) | -11.2M | |
| Normalized Net Income (MRQ) | -11.2M | |
| * Data above as of Dec 31, 2012 | ||
| Per Share Data | ACHN | |
| EPS excluding extraordinary items (TTM) | -0.64 | |
| EPS Normalized (MRFY) | -0.64 | |
| Rev per share (TTM) | 0.04 | |
| BV per share (MRQ) | 0.90 | |
| Tangible BV per share (MRQ) | 0.90 | |
| Cash per share (MRQ) | 0.82 | |
| Cash flow per share (TTM) | -0.63 | |
| Indicated Annual Dividend (US) | 0.00 | |
| * Data above as of Dec 31, 2012 | ||
| Short Interest | ACHN | |
| Shares Short (Current Month) | 13.1M | |
| Short Ratio | 11.2 | |
| Short Interest as % of Float | 13.57% | |
| Shares Short (Prior Month) | 12.7M | |
| * Data above as of Apr 30, 2013 | ||
Company Overview
Company Contact Info
Address
300 George Street
NEW HAVEN, CT 6511
Telephone
(203) 624-7000Fax
(203) 624-7003Website
http://www.achillion.com